Lack of association between methylenetetrahydrofolate reductase gene A1298C polymorphism and breast cancer susceptibility.
Mol Biol Rep
; 38(4): 2295-9, 2011 Apr.
Article
en En
| MEDLINE
| ID: mdl-21052845
ABSTRACT
Published data on the association between methylenetetrahydrofolate reductase gene (MTHFR) A1298C polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, and Web of Science were searched. Crude ORs with 95% CIs were used to assess the strength of association between the MTHFR A1298C polymorphism and breast cancer risk. The pooled ORs were performed for co-dominant model (AC vs. AA, CC vs. AA), dominant model (CC+AC vs. AA), and recessive model (CC vs. AC+AA), respectively. A total of 26 studies including 12,244 cases and 15,873 controls were involved in this meta-analysis. Overall, no significant associations were found between MTHFR A1298C polymorphism and breast cancer risk when all studies pooled into the meta-analysis (AC vs. AA OR=0.99, 95% CI 0.94-1.05; CC vs. AA OR 0.99, 95% CI 0.90-1.09; dominant model OR=0.99, 95% CI 0.95-1.04; and recessive model OR=0.98, 95% CI 0.90-1.08). In the subgroup analysis by ethnicity or study design, still no significant associations were found for all comparison models. In conclusion, this meta-analysis suggests that the MTHFR A1298C polymorphism may be not associated with breast cancer development. However, large sample and representative population-based studies with homogeneous breast cancer patients and well matched controls are warranted to confirm this finding.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Predisposición Genética a la Enfermedad
/
Polimorfismo de Nucleótido Simple
/
Metilenotetrahidrofolato Reductasa (NADPH2)
Tipo de estudio:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Systematic_reviews
Límite:
Female
/
Humans
Idioma:
En
Año:
2011
Tipo del documento:
Article